Drug profile · INN
diatrizoate meglumine
SINOGRAFIN
- US status
- approved
- Patents linked
- 0
- News articles
- 0
Quick answer
diatrizoate meglumine (SINOGRAFIN) is an FDA-listed pharmaceutical active ingredient. Route of administration: urethral. Current US regulatory status: approved.
Key facts
INN diatrizoate meglumine
Brand SINOGRAFIN
Route URETHRAL
Formulation INJECTABLE
Frequently asked questions
What is diatrizoate meglumine?
diatrizoate meglumine (SINOGRAFIN) is an FDA-listed pharmaceutical active ingredient. Route of administration: urethral. Current US regulatory status: approved.
What is the brand name for diatrizoate meglumine?
SINOGRAFIN is a marketed brand name for diatrizoate meglumine. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of diatrizoate meglumine?
diatrizoate meglumine has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.